Abstract
Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic
-
Administration, Intranasal
-
Animals
-
Antibodies, Viral / immunology
-
Coronavirus Nucleocapsid Proteins
-
Immunity, Cellular
-
Immunization, Secondary / methods
-
Immunoglobulin A / immunology
-
Injections, Intramuscular
-
Lipopeptides / immunology
-
Mice
-
Mice, Inbred BALB C
-
Nucleocapsid Proteins / immunology*
-
Severe Acute Respiratory Syndrome / immunology
-
Severe Acute Respiratory Syndrome / prevention & control*
-
Severe acute respiratory syndrome-related coronavirus / immunology*
-
Vaccinia virus / immunology
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / immunology*
Substances
-
Adjuvants, Immunologic
-
Antibodies, Viral
-
Coronavirus Nucleocapsid Proteins
-
Immunoglobulin A
-
Lipopeptides
-
Nucleocapsid Proteins
-
Viral Vaccines
-
macrophage stimulatory lipopeptide 2